Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

An evaluation of SNP frequency, aspirin resistance, and adenoma/colorectal cancer risk in the PLCO study

Principal Investigator
Name
Holli Loomans-Kropp
Degrees
Ph.D., M.P.H.
Institution
The Ohio State University
Position Title
Assistant Professor
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-978
Initial CDAS Request Approval
May 9, 2022
Title
An evaluation of SNP frequency, aspirin resistance, and adenoma/colorectal cancer risk in the PLCO study
Summary
A significant body of epidemiologic evidence suggests the preventive effects of long-term aspirin use for colorectal cancer. However, aspirin use does not prevent all colorectal cancers. To gain further insight into the genetic mechanisms through which aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), we propose to evaluate the association between single nucleotide polymorphism (SNP) frequency, aspirin/NSAID use, and colon adenoma and colorectal cancer risk. The results of this study will add knowledge to our understanding of aspirin resistance or sensitivity in cancer prevention.
Aims

Aim 1: An evaluation of the association between aspirin/NSAID use, SNP frequency and adenoma risk
Research question 1: What is the association between PLCO-examined SNPs and adenoma risk among aspirin users, compared to non-aspirin users?
Research question 2: What is the association between PLCO-examined SNPs and adenoma risk among NSAID users, compared to non-NSAID users?

Aim 2: An evaluation of the association between aspirin/NSAID use, SNP frequency and colorectal cancer risk
Research question 1: What is the association between PLCO-examined SNPs and colorectal cancer risk among aspirin users, compared to non-aspirin users?
Research question 2: What is the association between PLCO-examined SNPs and colorectal cancer risk among NSAID users, compared to non-NSAID users?

Aim 3: Compare significant SNPs found in Aim 1 to those found in Aim 2.

Collaborators

Asad Umar (National Cancer Institute), Paul Pinsky (National Cancer Institute), Daoud Meerzaman (National Cancer Institute)